Literature DB >> 29898879

Spontaneous reversion of a lineage switch following an initial blinatumomab-induced ALL-to-AML switch in MLL-rearranged infant ALL.

Matthias Wölfl1, Mareike Rasche2, Matthias Eyrich1, Renate Schmid1, Dirk Reinhardt2, Paul G Schlegel1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29898879      PMCID： PMC6020817          DOI： 10.1182/bloodadvances.2018018093

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  16 in total

1.  Lineage Switch in MLL-Rearranged Infant Leukemia Following CD19-Directed Therapy.

Authors:  Ahmad Rayes; Richard L McMasters; Maureen M O'Brien
Journal:  Pediatr Blood Cancer       Date:  2016-02-23       Impact factor: 3.167

2.  Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy.

Authors:  Rebecca Gardner; David Wu; Sindhu Cherian; Min Fang; Laïla-Aïcha Hanafi; Olivia Finney; Hannah Smithers; Michael C Jensen; Stanley R Riddell; David G Maloney; Cameron J Turtle
Journal:  Blood       Date:  2016-02-23       Impact factor: 22.113

3.  Lineage switch from B acute lymphoblastic leukemia to acute monocytic leukemia with persistent t(4;11)(q21;q23) and cytogenetic evolution under CD19-targeted therapy.

Authors:  Estelle Balducci; Vanessa Nivaggioni; John Boudjarane; Lakhdar Bouriche; Ilhem Rahal; Denis Bernot; Emilie Alazard; Nicolas Duployez; Nathalie Grardel; Isabelle Arnoux; Marina Lafage-Pochitaloff; Gérard Michel; Bertrand Nadel; Marie Loosveld
Journal:  Ann Hematol       Date:  2017-06-20       Impact factor: 3.673

4.  Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy.

Authors:  Elena Sotillo; David M Barrett; Kathryn L Black; Asen Bagashev; Derek Oldridge; Glendon Wu; Robyn Sussman; Claudia Lanauze; Marco Ruella; Matthew R Gazzara; Nicole M Martinez; Colleen T Harrington; Elaine Y Chung; Jessica Perazzelli; Ted J Hofmann; Shannon L Maude; Pichai Raman; Alejandro Barrera; Saar Gill; Simon F Lacey; Jan J Melenhorst; David Allman; Elad Jacoby; Terry Fry; Crystal Mackall; Yoseph Barash; Kristen W Lynch; John M Maris; Stephan A Grupp; Andrei Thomas-Tikhonenko
Journal:  Cancer Discov       Date:  2015-10-29       Impact factor: 39.397

5.  Hematopoietic stem cell involvement in BCR-ABL1-positive ALL as a potential mechanism of resistance to blinatumomab therapy.

Authors:  Inga Nagel; Marius Bartels; Johannes Duell; Hans-Heinrich Oberg; Sandra Ussat; Henrike Bruckmueller; Oliver Ottmann; Heike Pfeifer; Heiko Trautmann; Nicola Gökbuget; Almuth Caliebe; Dieter Kabelitz; Michael Kneba; Heinz-August Horst; Dieter Hoelzer; Max S Topp; Ingolf Cascorbi; Reiner Siebert; Monika Brüggemann
Journal:  Blood       Date:  2017-08-21       Impact factor: 22.113

Review 6.  Updates in the biology and therapy for infant acute lymphoblastic leukemia.

Authors:  Erin M Guest; Ronald W Stam
Journal:  Curr Opin Pediatr       Date:  2017-02       Impact factor: 2.856

7.  Lineage switch in childhood acute leukemia: an unusual event with poor outcome.

Authors:  Jorge G Rossi; Andrea R Bernasconi; Cristina N Alonso; Patricia L Rubio; Marta S Gallego; Carolina A Carrara; Myriam R Guitter; Silvia Eandi Eberle; Mariela Cocce; Pedro A Zubizarreta; María S Felice
Journal:  Am J Hematol       Date:  2012-06-08       Impact factor: 10.047

8.  Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.

Authors:  David T Teachey; Susan R Rheingold; Shannon L Maude; Gerhard Zugmaier; David M Barrett; Alix E Seif; Kim E Nichols; Erica K Suppa; Michael Kalos; Robert A Berg; Julie C Fitzgerald; Richard Aplenc; Lia Gore; Stephan A Grupp
Journal:  Blood       Date:  2013-05-15       Impact factor: 22.113

9.  Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.

Authors:  Shannon L Maude; Theodore W Laetsch; Jochen Buechner; Susana Rives; Michael Boyer; Henrique Bittencourt; Peter Bader; Michael R Verneris; Heather E Stefanski; Gary D Myers; Muna Qayed; Barbara De Moerloose; Hidefumi Hiramatsu; Krysta Schlis; Kara L Davis; Paul L Martin; Eneida R Nemecek; Gregory A Yanik; Christina Peters; Andre Baruchel; Nicolas Boissel; Francoise Mechinaud; Adriana Balduzzi; Joerg Krueger; Carl H June; Bruce L Levine; Patricia Wood; Tetiana Taran; Mimi Leung; Karen T Mueller; Yiyun Zhang; Kapildeb Sen; David Lebwohl; Michael A Pulsipher; Stephan A Grupp
Journal:  N Engl J Med       Date:  2018-02-01       Impact factor: 91.245

10.  Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis.

Authors:  C L Haddox; A A Mangaonkar; D Chen; M Shi; R He; J L Oliveira; M R Litzow; A Al-Kali; W J Hogan; M A Elliott
Journal:  Blood Cancer J       Date:  2017-09-15       Impact factor: 11.037
View more
  13 in total

Review 1.  Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia.

Authors:  Joseph Wynne; David Wright; Wendy Stock
Journal:  Blood Adv       Date:  2019-01-08

Review 2.  Taking a "BiTE out of ALL": blinatumomab approval for MRD-positive ALL.

Authors:  Emily Curran; Wendy Stock
Journal:  Blood       Date:  2019-02-22       Impact factor: 22.113

3.  CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.

Authors:  Vinodh Pillai; Kavitha Muralidharan; Wenzhao Meng; Asen Bagashev; Derek A Oldridge; Jaclyn Rosenthal; John Van Arnam; Jos J Melenhorst; Diwakar Mohan; Amanda M DiNofia; Minjie Luo; Sindhu Cherian; Jonathan R Fromm; Gerald Wertheim; Andrei Thomas-Tikhonenko; Michele Paessler; Carl H June; Eline T Luning Prak; Vijay G Bhoj; Stephan A Grupp; Shannon L Maude; Susan R Rheingold
Journal:  Blood Adv       Date:  2019-11-26

Review 4.  Beyond the storm - subacute toxicities and late effects in children receiving CAR T cells.

Authors:  Haneen Shalabi; Juliane Gust; Agne Taraseviciute; Pamela L Wolters; Allison B Leahy; Carlos Sandi; Theodore W Laetsch; Lori Wiener; Rebecca A Gardner; Veronique Nussenblatt; Joshua A Hill; Kevin J Curran; Timothy S Olson; Colleen Annesley; Hao-Wei Wang; Javed Khan; Marcelo C Pasquini; Christine N Duncan; Stephan A Grupp; Michael A Pulsipher; Nirali N Shah
Journal:  Nat Rev Clin Oncol       Date:  2021-01-25       Impact factor: 66.675

5.  B/T mixed phenotype acute leukemia with high hyperdiploidy and lineage switch to B-cell acute leukemia.

Authors:  Hanaa Skhoun; Mohammed Khattab; Zahra Takki Chebihi; Aziza Belkhayat; Nadia Dakka; Jamila El BaghdadI
Journal:  Leuk Res Rep       Date:  2022-01-15

6.  Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL.

Authors:  Yaqi Zhao; Ibrahim Aldoss; Chunxu Qu; Jeremy Chase Crawford; Zhaohui Gu; Emma K Allen; Anthony E Zamora; Thomas B Alexander; Jeremy Wang; Hiroaki Goto; Toshihiko Imamura; Koshi Akahane; Guido Marcucci; Anthony S Stein; Ravi Bhatia; Paul G Thomas; Stephen J Forman; Charles G Mullighan; Kathryn G Roberts
Journal:  Blood       Date:  2021-01-28       Impact factor: 22.113

Review 7.  Personalized therapy in pediatric high-risk B-cell acute lymphoblastic leukemia.

Authors:  Seth E Karol; Ching-Hon Pui
Journal:  Ther Adv Hematol       Date:  2020-06-02

8.  Immunotherapy- (Blinatumomab-) Related Lineage Switch of KMT2A/AFF1 Rearranged B-Lymphoblastic Leukemia into Acute Myeloid Leukemia/Myeloid Sarcoma and Subsequently into B/Myeloid Mixed Phenotype Acute Leukemia.

Authors:  Rui R He; Zacharia Nayer; Matthew Hogan; Raymund S Cuevo; Kimberly Woodward; David Heyer; Christine A Curtis; Jess F Peterson
Journal:  Case Rep Hematol       Date:  2019-12-07

Review 9.  Evaluating Blinatumomab for the Treatment of Relapsed/Refractory ALL: Design, Development, and Place in Therapy.

Authors:  Audrey M Sigmund; Kieran D Sahasrabudhe; Bhavana Bhatnagar
Journal:  Blood Lymphat Cancer       Date:  2020-11-03

Review 10.  The Origin of B-cells: Human Fetal B Cell Development and Implications for the Pathogenesis of Childhood Acute Lymphoblastic Leukemia.

Authors:  Thomas R Jackson; Rebecca E Ling; Anindita Roy
Journal:  Front Immunol       Date:  2021-02-17       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.